Released on: January 14, 2008, 10:06 am

Press Release Author: Samaritan Pharmaceuticals

Industry: Biotech

Press Release Summary: has signed an exclusive license for the marketing and sales
of U.S. approved Infasurf (calfactant), a specialist medication used to treat and
prevent respiratory distress syndrome (RDS) in premature infants. Under this
agreement, Samaritan has obtained exclusive rights to sell Infasurf in Turkey,
Serbia, Bosnia, Macedonia, Albania, Egypt and Syria. The cumulative population of
these countries is greater than 180 million people.

Press Release Body: - ONY\'s Neonatal U.S. Approved Drug Infasurf to Treat
Respiratory Distress Syndrome in Premature Infants In-Licensed

- Marketing and Sales Rights Granted for Turkey, Serbia, Bosnia, Macedonia, Albania,
Egypt and Syria


Samaritan Pharmaceuticals Inc. (AMEX:LIV - News), a developer of innovative drugs,
is pleased to announce that it has signed an exclusive license for the marketing and
sales of U.S. approved Infasurf (calfactant), a specialist medication used to treat
and prevent respiratory distress syndrome (RDS) in premature infants. Under this
agreement, Samaritan has obtained exclusive rights to sell Infasurf in Turkey,
Serbia, Bosnia, Macedonia, Albania, Egypt and Syria. The cumulative population of
these countries is greater than 180 million people.

Infasurf is successfully marketed and sold in the United States by Forest
Laboratories, Inc. (NYSE:FRX - News) and is manufactured by ONY Inc., a U.S. drug
development company and a pioneer in the field of Surfactant research. The decision
to license the exclusive rights to Infasurf to Samaritan was based on the expertise
of the Samaritan team and their proven track record in regulatory affairs and in the
marketing and sales of specialty products in Eastern Europe. Samaritan will register
Infasurf with the health authorities in the licensed countries.

Infasurf is a specialist medication used to treat and prevent respiratory distress
syndrome (RDS), a lung condition that can occur in prematurely born infants whose
lungs have not completely developed. RDS occurs when infants lack surfactant, a
natural substance normally produced in the body, which is necessary for lungs to
function normally.

Infasurf is a bovine-derived, natural surfactant. Its unique advantages include a
high concentration of Surfactant Proteins -- and in particular Surfactant Protein
Type B (SP-B). SP-B is vital for normal lung function (babies genetically lacking
SP-B die soon after birth). Infasurf is approved by the U.S. FDA for the treatment
or prevention of Infant Respiratory Distress Syndrome.

In composition, Infasurf is the closest surfactant to natural surfactant. Infasurf
contains approximately 2% proteins (0.7% SP-B) as well as DPPC, Cholesterol and
other surface-active agents. Its benefits are,

Infasurf is fast acting and excellent value for money.
Infasurf can be administered by either side port or catheter.
Infasurf is derived from cattle and thus contains no pork or pig products and is
thus not objectionable to Muslims.
Infasurf has been used in over 100,000 infants.
***

http://www.infasurf.net

***

Samaritan Pharmaceuticals: ``We LIV...to Save Lives.\'\'

Samaritan is a small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics for AIDS, Alzheimer\'s, Cancer and Heart disease patients.
Look at http://www.samaritanpharma.com. Please register on Website so we can notify
you of upcoming conference calls, news and events.

***

The company disclaims any information that is created by an outside party and
endorses only information that is communicated by its press releases, filings and
Website. This news release contains forward-looking statements that reflect
management\'s current beliefs about the potential for its drug candidates, science
and technology. However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and regulatory
review. There are no guarantees that products will prove to be commercially
successful. For additional information about the factors that affect the company\'s
business, please read the company\'s latest Form 10-K/A filed November 2, 2006. The
company undertakes no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001


Web Site: http://www.samaritanpharma.com

Contact Details: Samaritan Pharmaceuticals, Inc.
101 convention center Drive
Suite 310
Las vegas, NV 89109
702-735-7001
info@samaritanpharma.com